Atlas Trials

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

Clinical trial NCT04158687 · COMPLETED

Trial details

NCT number
NCT04158687
Sponsor
Concert Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2019-11-26
Primary completion
2020-12-22
Enrollment
326

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.